Technology and Innovation
With the animating philosophy of treating the treatable, preventing the preventable, and transcending the inevitable, we focus on the best modalities for treatment, disease monitoring, minimizing the chance for recurrence, and being prepared for the worst-case scenario.
We extend our research beyond the boundaries of any healthcare system, supporting our clients with an unlimited time commitment—anytime and anywhere.
We are there remotely and in person when desired to minimize the regret factor, ensuring our clients never look back with the regret of not being aware of all available options.
All of the services below are facilitated and coordinated by the Rhodium team at Rango. Rhodium brings together a global network of world-class vendors, researchers, and treatment centers, enabling our clients to access extraordinary services with streamlined processes and expert advocacy. Our team conducts the research, builds the connections, and ensures seamless access and integration across all aspects of care.
Where Things Are Now
Review of All Diagnostic Work That Has Been Done
We begin by conducting a meticulous review of every diagnostic test our client has undergone—imaging, pathology, molecular testing, and laboratory data. This retrospective analysis helps us reconstruct the full narrative of the disease, identify any overlooked opportunities, and determine whether additional or more advanced diagnostics are warranted. The Rhodium team ensures that all previous data is examined by top experts from our network, guaranteeing a complete and precise understanding of the past.
Monitoring for Progression
Identify Advanced Options for Disease Monitoring Using Liquid Biopsies Including Ctdna, Ctrna, Ctc, Xtexosome, Etc.
To monitor disease activity with the highest sensitivity, we explore cutting-edge liquid biopsy technologies that provide dynamic, real-time insights into tumour burden and molecular evolution. These non-invasive tests analyse circulating tumour DNA (ctDNA), circulating tumour RNA (ctRNA), circulating tumour cells (CTCs), and extracellular vesicles such as exosomes (XtExosome). The Rhodium team facilitates access to the most advanced labs and vendors globally, ensuring each client benefits from the most precise monitoring tools available.
Understanding What Will Work
Identify and Deploy in Vitro, in Vivo and in Silico Tests to Predict Response to Treatment
Understanding how a tumour will respond to specific therapies is key to personalizing treatment. We integrate laboratory-based (in vitro), animal model-based (in vivo), and computational (in silico) platforms to test various treatments against the patient’s unique cancer profile. Rhodium coordinates these predictive tests through its trusted partners, reducing trial-and-error and supporting informed decision-making with customized, research-driven insights.
Expert Input
KOL Tumor Panel
Each case can be reviewed by a Key Opinion Leader (KOL) tumour board—an elite panel of global experts from relevant fields. This multidisciplinary review process integrates diverse insights and ensures that no critical consideration is missed. Rhodium convenes and moderates these panels, drawing on our international relationships to assemble the most relevant minds for each client’s case. (*Not included in the base package. Can be added at any time)
In-Depth AI-Facilitated Research Using Different Agents Trained to Advocate
Our approach to research leverages a suite of AI tools and agents trained in oncology, pharmacology, and genomics. These digital advocates conduct ongoing scans of global databases, clinical trials, and case studies to surface relevant, emerging options. Rhodium’s AI resources are continuously learning and evolving, coordinated by our human team to ensure that each case is paired with personalized, evidence-based strategies from across the world. Data integration is via CureWise.
Treatment Possibilities
Access to Most Advanced Radiation Therapies (e.g. Proton Beam, Carbon Ion, Tomo-Therapy)
Understanding how a tumour will respond to specific therapies is key to personalizing treatment. We integrate laboratory-based (in vitro), animal model-based (in vivo), and computational (in silico) platforms to test various treatments against the patient’s unique cancer profile. Rhodium coordinates these predictive tests through its trusted partners, reducing trial-and-error and supporting informed decision-making with customized, research-driven insights.
Access to Advanced Cellular Immunotherapies, Specifically Nk Cells Enrichment, Cancer Vaccines (Neo-Epitope, Dendritic Cells, Tumour and Vaccine Infiltrating Lymphocytes, Evolving Mrna Vaccines), Car-T and Tcr Therapies
We identify and facilitate access to the frontier of cellular immunotherapy. This includes natural killer (NK) cell enrichment to augment innate immune responses, personalized cancer vaccines targeting neo-epitopes and tumour-specific antigens, and advanced modalities like CAR-T and TCR therapies designed to genetically enhance T-cell targeting. The Rhodium team navigates the complex logistics and regulatory pathways, connecting clients to the right clinical trials, manufacturers, and immunotherapy centres.
The Use of a Client-Designed Protocol of Repurposed Drugs
In collaboration with each client and their care team, we design personalized protocols incorporating repurposed drugs—approved medications originally developed for other conditions but shown to have anti-cancer properties. Rhodium helps identify these medications, assess scientific evidence, and coordinate their use safely and effectively, integrating them with other therapies as needed.
Targeted Drug Therapies Based on Sequencing Data
Using comprehensive genomic sequencing—whole exome, whole genome, or targeted panels—we uncover actionable mutations, fusions, and expression profiles that can be matched with precision drugs. Rhodium ensures access to the best sequencing platforms and expert molecular tumour boards to interpret the results. We then coordinate sourcing and administration of the matched targeted therapies through our trusted pharmacy and provider networks.
Oncolytic viruses
Oncolytic virotherapy is an emerging modality that uses genetically modified viruses to selectively infect and destroy cancer cells while stimulating systemic immune responses. Rhodium identifies global research centres and clinical trials offering access to these advanced agents and manages the referral, eligibility screening, and integration into the client’s broader care plan.
Integrative oncology
True healing goes beyond pharmaceuticals and procedures. Our integrative oncology framework supports patients through evidence-informed complementary therapies—nutrition, acupuncture, stress management, exercise, and mind-body practices—that optimize physical resilience, reduce treatment-related side effects, and support emotional well-being. The Rhodium team curates and coordinates access to leading integrative practitioners worldwide, ensuring a truly holistic support system that treats the person, not just the disease. (*Not included in the base package. Can be added at any time)